Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCMOP Sequential Therapy for Intermediate-to-High Risk DLBCL
NCT05990985Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in diffuse large B-cell lymphoma (DLBCL), sponsored by The First Hospital of Jilin University. Primary endpoint: Objective Response Rate. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05990985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990985.